Abivax celebrates Nobel Prize for microRNA discovery

Abivax congratulated Victor Ambros and Gary Ruvkun on winning the Nobel Prize in Physiology or Medicine. Their discovery of microRNA, which is crucial in post-transcriptional gene regulation, marked a turning point in scientific research. Marc de Garidel, CEO of Abivax, said the recognition highlights the importance of microRNA in therapy.

Abivax, a biotech company specializing in chronic inflammatory diseases, is developing the drug obefazimod. The latter, focused on microRNA-124, is currently in clinical trials for ulcerative colitis and Crohn's disease. Didier Scherrer, Abivax's Chief Scientific Officer, expresses his enthusiasm for the prospects offered by this discovery for future treatments.